CA3075688A1 - Preeclampsia biomarkers and related systems and methods - Google Patents

Preeclampsia biomarkers and related systems and methods Download PDF

Info

Publication number
CA3075688A1
CA3075688A1 CA3075688A CA3075688A CA3075688A1 CA 3075688 A1 CA3075688 A1 CA 3075688A1 CA 3075688 A CA3075688 A CA 3075688A CA 3075688 A CA3075688 A CA 3075688A CA 3075688 A1 CA3075688 A1 CA 3075688A1
Authority
CA
Canada
Prior art keywords
proteins
preeclampsia
probes
clec4a
kim1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3075688A
Other languages
English (en)
French (fr)
Inventor
Matthew Cooper
Sharat Singh
Karen A. F. COPELAND
Lyndal HESTERBERG
Amin R. MAZLOOM
Mohammad Abbasi
Richard Giulio Del Mastro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biora Therapeutics Inc
Original Assignee
Progenity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenity Inc filed Critical Progenity Inc
Publication of CA3075688A1 publication Critical patent/CA3075688A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/471—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
CA3075688A 2017-09-13 2018-09-13 Preeclampsia biomarkers and related systems and methods Abandoned CA3075688A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762558184P 2017-09-13 2017-09-13
US62/558,184 2017-09-13
PCT/US2018/050893 WO2019055661A1 (en) 2017-09-13 2018-09-13 PRE-ÉCLAMPSIE BIOMARKERS AND ASSOCIATED SYSTEMS AND METHODS

Publications (1)

Publication Number Publication Date
CA3075688A1 true CA3075688A1 (en) 2019-03-21

Family

ID=65723874

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3075688A Abandoned CA3075688A1 (en) 2017-09-13 2018-09-13 Preeclampsia biomarkers and related systems and methods

Country Status (10)

Country Link
US (3) US20200264188A1 (OSRAM)
EP (1) EP3682250A4 (OSRAM)
JP (1) JP2020533595A (OSRAM)
KR (1) KR20200109293A (OSRAM)
CN (1) CN111094988A (OSRAM)
AU (1) AU2018331400A1 (OSRAM)
CA (1) CA3075688A1 (OSRAM)
MX (1) MX2020002788A (OSRAM)
SG (1) SG11202002065VA (OSRAM)
WO (1) WO2019055661A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200264188A1 (en) 2017-09-13 2020-08-20 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECLAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR TESTS
GB202012830D0 (en) * 2020-08-17 2020-09-30 Univ Tartu Method of prognosing preeclampsia
AU2022270155B2 (en) * 2021-05-07 2025-09-11 University Of North Texas Health Science Center At Fort Worth Blood test to screen out parkinson's disease
CN113724873B (zh) * 2021-08-31 2024-01-12 陕西佰美基因股份有限公司 一种基于mlp多平台校准的子痫前期风险预测方法
AU2022201995A1 (en) * 2022-01-27 2023-08-10 Speclipse, Inc. Liquid refining apparatus and diagnosis system including the same
CN114878837A (zh) * 2022-05-31 2022-08-09 国家卫生健康委科学技术研究所 与妊娠期高血压疾病诊断相关的血清预测标志物
CN117012276A (zh) * 2023-06-30 2023-11-07 佛山市妇幼保健院 子痫前期溶酶体相关生物标志物的筛选方法及其应用
CN119206371B (zh) * 2024-11-22 2025-05-13 南京红十字血液中心 一种基于机器学习的血型辅助研判方法

Family Cites Families (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777964A (en) 1986-01-02 1988-10-18 David Briggs System for obtaining blood samples and submitting for testing of aids
US5223440A (en) 1987-11-17 1993-06-29 Adeza Biomedical Corporation Ex vivo product of conception test to determine abortion
US5096830A (en) 1987-11-17 1992-03-17 Adeza Biomedical Corporation Preterm labor and membrane rupture test
US4919889A (en) 1988-09-15 1990-04-24 Aspen Diagnostics Corporation Sample collection and transport fluid composition
US5281522A (en) 1988-09-15 1994-01-25 Adeza Biomedical Corporation Reagents and kits for determination of fetal fibronectin in a vaginal sample
DE69231636T2 (de) 1991-11-04 2001-05-23 Adeza Biomedical Corp Screeningverfahren zur identifizierung von frauen mit erhöhtem frühgeburtsrisiko
WO1993009432A1 (en) 1991-11-04 1993-05-13 Adeza Biomedical Corporation Screening method for identifying women at increased risk for imminent delivery
US5516702A (en) 1991-11-06 1996-05-14 Adeza Biomedical Corporation Screening method for identifying women at increased risk for imminent delivery
US5898005A (en) 1993-02-24 1999-04-27 Dade Behring Inc. Rapid detection of analytes with receptors immobilized on soluble submicron particles
AU6267794A (en) 1993-02-24 1994-09-14 Dade International Inc. Immobilization of specific binding assay reagents
EP0689552B1 (en) 1993-03-23 2002-10-30 VOROTELIAK, Victor A method of detecting rupture of the amniotic membranes in pregant mammals
US5431171A (en) 1993-06-25 1995-07-11 The Regents Of The University Of California Monitoring fetal characteristics by radiotelemetric transmission
CA2170873A1 (en) 1993-09-03 1995-03-09 Dariush Davalian Fluorescent oxygen channeling immunoassays
US5650394A (en) 1993-11-04 1997-07-22 Adeza Biomedical Use of urinastatin-like compounds to prevent premature delivery
US5597700A (en) 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
US6140099A (en) 1994-05-20 2000-10-31 The Trustees Of The University Of Pennsylvania Method of delaying fetal membrane rupture by inhibiting matrix metalloproteinase-9 activity
US5641636A (en) 1994-05-20 1997-06-24 University Of Pennsylvania Method of predicting fetal membrane rupture based on matrix metalloproteinase-9 activity
JP3064015B2 (ja) 1995-01-26 2000-07-12 メルク フロスト カナダ アンド カンパニー プロスタグランジンレセプターｄｐ
ATE315048T1 (de) 1995-10-31 2006-02-15 Maruha Corp Monoklonaler antikoerper spezifisch fuer prostaglandin d synthetase
US6678669B2 (en) 1996-02-09 2004-01-13 Adeza Biomedical Corporation Method for selecting medical and biochemical diagnostic tests using neural network-related applications
US6120460A (en) 1996-09-04 2000-09-19 Abreu; Marcio Marc Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions
US6544193B2 (en) 1996-09-04 2003-04-08 Marcio Marc Abreu Noninvasive measurement of chemical substances
FI963989L (fi) 1996-10-04 1998-04-05 Wallac Oy Homogeenisiä määritysmenetelmiä, jotka perustuvat luminesenssienergiasiirtoon
US6376199B1 (en) 1997-03-07 2002-04-23 The Hospital For Sick Children (Hsc) Methods to diagnose a required regulation of trophoblast invasion
US6875567B1 (en) 1997-11-10 2005-04-05 Genentech, Inc. Method of detecting cardiac hypertrophy through probe hybridization and gene expression analysis
US6610480B1 (en) 1997-11-10 2003-08-26 Genentech, Inc. Treatment and diagnosis of cardiac hypertrophy
US20020031513A1 (en) 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
US6267722B1 (en) 1998-02-03 2001-07-31 Adeza Biomedical Corporation Point of care diagnostic systems
US6394952B1 (en) 1998-02-03 2002-05-28 Adeza Biomedical Corporation Point of care diagnostic systems
US6506789B2 (en) 1998-06-03 2003-01-14 Shionogi & Co., Ltd. Methods for the treatment of itching comprising administering PGD2 receptor antagonist
US20010025140A1 (en) 1998-07-22 2001-09-27 Torok Brian A. System for identifying premature rupture of membrane during pregnancy
US6149590A (en) 1998-07-22 2000-11-21 Smith; Ramada S. System for identifying premature rupture of membrane during pregnancy
US6126597A (en) 1998-07-22 2000-10-03 Smith; Ramada S. System for identifying premature rupture of membrane during pregnancy
US7109044B1 (en) 1998-09-04 2006-09-19 Maruha Corporation Method of detection and disease state management for renal diseases
TR200101882T2 (tr) 1998-10-29 2001-12-21 Board Of Regents, The University Of Texas System Tiazolidindion türevlerinin erken doğum halinde uterus kasılmalarını veya laktasyonu önlemek için kullanımı
JP2000249709A (ja) 1999-02-26 2000-09-14 Maruha Corp 冠血管インターベンション施行後の再狭窄の予測方法
US6126616A (en) 1999-06-21 2000-10-03 Sanyal; Mrinal K. Collection of biological products from human accessory reproductive organs by absorbent systems
JP3486408B2 (ja) 1999-08-23 2004-01-13 株式会社ビー・エム・エル 物質のヒトプロスタグランジンｄ２受容体に対する性質の同定方法
FR2809182B1 (fr) 2000-05-18 2003-08-15 Univ Rene Descartes Detection de l'il-6 pour la prevision des risques d'accouchement premature
US20010053876A1 (en) 2000-06-15 2001-12-20 Torok Brian A. System for identifying premature rupture of membrane during pregnancy
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
US7314727B2 (en) 2000-07-21 2008-01-01 Maruha Corporation Methods to facilitate diagnosis of normal pressure hydrocephalus
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
US20020046054A1 (en) 2000-08-28 2002-04-18 Morand Patrick G. Use of blood and plasma donor samples and data in the drug discovery process
US7217725B2 (en) 2000-09-14 2007-05-15 Allergan, Inc. Prostaglandin D2 antagonist
US20040157222A1 (en) 2000-10-16 2004-08-12 Alex Smolyar Regulation of human dendritic cell immunoreceptor
US7635571B2 (en) 2000-12-07 2009-12-22 Siemens Healthcare Diagnostics Products Gmbh Amplified signal in binding assays
ATE340796T1 (de) 2001-05-23 2006-10-15 Merck Frosst Canada Inc Dihydropyrrolo(1,2-aöindol- und tetrahydropyrido)1,2-aöindolderivate als prostaglandin rezeptor antagonisten
CA2454347A1 (en) 2001-07-18 2003-01-30 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Eosinophil prostaglandin d2 receptor assays
US20040197834A1 (en) 2001-07-20 2004-10-07 Francois Gervais Method to increase expression of pgd2 receptors and assays for identifying modulators of prostaglandin d2 receptors
US20050101841A9 (en) 2001-12-04 2005-05-12 Kimberly-Clark Worldwide, Inc. Healthcare networks with biosensors
AU2003247667A1 (en) 2002-07-01 2004-01-19 University Of Rochester Medical Center Method for determination of likelihood of occurrence of preterm labor in pregnant females
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
BRPI0312818B8 (pt) 2002-07-19 2021-05-25 Beth Israel Deaconess Medical Ct Inc uso de uma medida do nível do polipeptídeo sflt-1 em uma amostra de uma paciente e uso de uma medida dos níveis de pelo menos dois dos peptídeos sflt1, vegf livre ou polipeptídio pigf livre em uma amostra de um paciente usando um métrico
DK2204654T3 (da) 2002-08-13 2013-03-11 N Dia Inc Anordninger og fremgangsmåder til detektering af fostervand i vaginalsekretioner
WO2004021012A2 (en) 2002-08-29 2004-03-11 Diagnostic Technologies Ltd. Method of diagnosis of pregnancy-related complications
JPWO2004030674A1 (ja) 2002-09-30 2006-01-26 塩野義製薬株式会社 プロスタグランジンｄ▲下２▼、プロスタグランジンｄ▲下２▼アゴニストおよびプロスタグランジンｄ▲下２▼アンタゴニストの新規用途
WO2004037206A2 (en) 2002-10-23 2004-05-06 University Of Hawaii Methods for diagnosing and treating pre-term labor
US20040100376A1 (en) 2002-11-26 2004-05-27 Kimberly-Clark Worldwide, Inc. Healthcare monitoring system
EP1590664A4 (en) 2003-02-05 2007-05-23 Ciphergen Biosystems Inc NON-INVASIVE ASSESSMENT OF THE INTRA-NAMINE ENVIRONMENT
ATE553378T1 (de) 2003-02-06 2012-04-15 Hologic Inc Screening und behandlungsverfahren zur vorbeugung von frühgeburten
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
US8068990B2 (en) 2003-03-25 2011-11-29 Hologic, Inc. Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids
US8003765B2 (en) 2003-04-09 2011-08-23 Stony Brook Anaesthesiology, University Faculty Practice Corporation Methods, antibodies and kits for detecting cerebrospinal fluid in a sample
US20070003992A1 (en) 2003-04-09 2007-01-04 Pentyala Srinivas N Methods and kits for detecting cerebrospinal fluid in a sample
US20040203079A1 (en) 2003-04-09 2004-10-14 Research Foundation Of The State University Of New York Methods and kits for detecting cerebrospinal fluid in a sample
WO2004098389A2 (en) 2003-05-02 2004-11-18 Johns Hopkins University Devices, systems and methods for bioimpendence measurement of cervical tissue and methods for diagnosis and treatment of human cervix
EP1631547A1 (en) 2003-05-20 2006-03-08 Merck Frosst Canada Ltd. Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin d2 antagonists
WO2005007223A2 (en) 2003-07-16 2005-01-27 Sasha John Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
JP3897117B2 (ja) 2003-09-24 2007-03-22 マルハ株式会社 妊娠中毒症の重症度判定と予知方法、および妊娠中毒症における胎児・胎盤機能の評価方法
US20080233597A1 (en) 2003-09-26 2008-09-25 Yasuhiko Shiina Method of Detecting or Differentiating Rheumatoid Arthritis and Method of Determining Stage of Disease or Degree of Dysfunction with Regard to Rheumatoid Arthritis
US20050131287A1 (en) 2003-12-16 2005-06-16 Kimberly-Clark Worldwide, Inc. Detection of premature rupture of the amniotic membrane
US20060024722A1 (en) 2004-07-30 2006-02-02 Mark Fischer-Colbrie Samples for detection of oncofetal fibronectin and uses thereof
US20080090759A1 (en) 2004-08-30 2008-04-17 Robert Kokenyesi Methods and kits for predicting risk for preterm labor
US20080254479A1 (en) 2004-08-30 2008-10-16 Cervimark, Llc Methods and Kits For Predicting Risk For Preterm Labor
WO2006034507A2 (en) 2004-09-24 2006-03-30 Beth Israel - Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
GT200500284A (es) 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
ATE519109T1 (de) 2004-12-21 2011-08-15 Univ Yale Präeklampsie-diagnose
US20060166242A1 (en) 2005-01-06 2006-07-27 Mount Sinai Hospital Markers of pre-term labor
DOP2006000016A (es) 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
CA2602963A1 (en) * 2005-03-24 2006-09-28 Beth Israel Deaconess Medical Center Methods of diagnosing fetal trisomy 13 or a risk of fetal trisomy 13 during pregnancy
US20070128589A1 (en) 2005-07-13 2007-06-07 Sanders Mitchell C Substrates, sensors, and methods for assessing conditions in females
JP5064219B2 (ja) 2005-07-22 2012-10-31 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
EP1937709A4 (en) 2005-09-15 2011-06-08 Swiss Asian Property Ltd MARKER FOR EARLY BLEEDING (PROM)
GT200600457A (es) 2005-10-13 2007-04-27 Aventis Pharma Inc Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2
US8076315B2 (en) 2005-10-14 2011-12-13 The Board Of Trustees Of The University Of Illinois Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
US20070111326A1 (en) 2005-11-14 2007-05-17 Abbott Laboratories Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia
US20080009552A1 (en) 2006-03-23 2008-01-10 Craig Pennell Markers of pre-term labor
AR060403A1 (es) 2006-04-12 2008-06-11 Sanofi Aventis Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2
HUE030850T2 (en) 2006-06-16 2017-06-28 Univ Pennsylvania Prostaglandin D2 receptor antagonists for the treatment of hair loss
AU2007276885A1 (en) 2006-07-25 2008-01-31 Sanofi-Aventis 2-phenyl-indoles as prostaglandin D2 receptor antagonists
US8133859B2 (en) 2006-09-27 2012-03-13 The United States Of America As Represented By The Department Of Health And Human Services SCGB3A2 as a growth factor and anti-apoptotic agent
EP2918288B1 (en) 2006-10-03 2017-08-16 Genzyme Corporation Use of TGF beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia
WO2008073491A1 (en) 2006-12-11 2008-06-19 University Of Florida Research Foundation, Inc. System and method for analyzing progress of labor and preterm labor
JP2010513458A (ja) 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用
JP5194212B2 (ja) 2006-12-26 2013-05-08 ブリガム・ヤング・ユニバーシティ 血清プロテオミクスシステムと関連する方法
CA2679198C (en) 2007-02-26 2011-07-12 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
US20090058072A1 (en) 2007-08-30 2009-03-05 Shirlee Ann Weber Record sheets with integrated themes
US20100251394A1 (en) 2007-09-20 2010-09-30 The Johns Hopkins University Treatment and prevention of ischemic brain injury
WO2009059259A2 (en) 2007-10-31 2009-05-07 Children's Hospital Medical Center Detection of worsening renal disease in subjects with systemic lupus erythematosus
US20110002866A1 (en) 2007-10-31 2011-01-06 Lubit Beverly W Methods to prevent a hair-related side effect of treatment with a chemotherapeutic agent
WO2009061681A2 (en) 2007-11-06 2009-05-14 Amira Pharmaceuticals, Inc Antagonists of pgd2 receptors
US20130177485A1 (en) 2007-11-27 2013-07-11 Momtec Life Ltd. Of Yazmot Haemek Diagnostic device for identifying rupture of membrane during pregnancy
US20110065139A1 (en) 2007-11-27 2011-03-17 Jacob Mullerad diagnostic device for identifying rupture of membrane during pregnancy
NZ585888A (en) 2007-12-14 2012-02-24 Pulmagen Therapeutics Asthma Ltd Indoles and their therapeutic use
US8835183B2 (en) 2008-01-07 2014-09-16 Ortho-Clinical Diagnostics, Inc. Determination of sFlt-1:angiogenic factor complex
US20110060026A1 (en) 2008-01-18 2011-03-10 George Hynd Indoles Active on CRTH2 Receptor
EP2245180B1 (en) 2008-01-25 2014-06-18 PerkinElmer Health Sciences, Inc. Methods for determining the risk of prenatal complications
WO2009097579A1 (en) 2008-01-30 2009-08-06 Proteogenix, Inc. Gestational age dependent proteomic changes of human maternal serum for monitoring maternal and fetal health
WO2009097584A1 (en) 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
UA98839C2 (en) 2008-02-01 2012-06-25 Панмира Фармасьютикалз, Ллк. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
CA2713139C (en) 2008-02-01 2013-04-23 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
EP2257536A4 (en) 2008-02-14 2011-03-23 Amira Pharmaceuticals Inc CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
EP2245022A4 (en) 2008-02-25 2012-02-22 Panmira Pharmaceuticals Llc ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
AU2009246116B2 (en) 2008-05-16 2013-02-14 Corthera, Inc. Method of preventing premature delivery
US20110112134A1 (en) 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
JP2011526281A (ja) 2008-06-24 2011-10-06 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のシクロアルカン［ｂ］インドールアンタゴニスト
CA2729292C (en) 2008-07-03 2013-09-03 Amira Pharmaceuticals, Inc. Phenoxyphenyl sulfide, sulfinyl and sulfonyl antagonists of prostaglandin d2 receptors
FR2934681B1 (fr) 2008-07-29 2011-09-30 Bastien Karkouche Dispositif pour la capture de particules biologiques et utilisation.
AU2009279809A1 (en) 2008-08-04 2010-02-11 Risk Assessment Labs, L.L.C. Multiplexed diagnostic test for preterm labor
BRPI0919004A2 (pt) 2008-09-22 2019-09-24 Cayman Chem Co composto de multiheteroarila como inibidores de h-pgds e sua utilização para o tratamento de doenças mediadas por prostaglandina d2
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
US9180114B2 (en) 2008-11-26 2015-11-10 President And Fellows Of Harvard College Neurodegenerative diseases and methods of modeling
WO2010085820A2 (en) 2009-01-26 2010-07-29 Amira Pharmaceuticals, Inc. Tricyclic compounds as antagonists of prostaglandin d2 receptors
US20120046261A1 (en) 2009-02-27 2012-02-23 University Of Utah Research Foundation Compositions and methods for diagnosing and preventing spontaneous preterm birth
GB0905964D0 (en) 2009-04-06 2009-05-20 King S College London Marker
CN102596902A (zh) 2009-08-05 2012-07-18 潘米拉制药公司 Dp2拮抗剂及其用途
US20110090048A1 (en) 2009-09-29 2011-04-21 Li Conan K Data Transmission Device with User Identification Capability
AU2010313447A1 (en) 2009-10-29 2012-05-31 The Trustees Of The University Of Pennsylvania Method of predicting risk of preterm birth
CA2778838A1 (en) 2009-11-12 2011-05-19 Cervilenz Inc. Devices and methods for cervix measurement
ES2677944T3 (es) 2009-11-25 2018-08-07 Hologic Inc. Detección de infección intraamniótica
US20120238469A1 (en) 2009-12-08 2012-09-20 Cedars-Sinai Medical Center Diagnostic biomarker to identify women at risk for preterm delivery
US8874183B2 (en) 2010-02-18 2014-10-28 The Johns Hopkins University Preterm labor monitor
AR080590A1 (es) 2010-03-16 2012-04-18 Aventis Pharma Inc Pirimidinas sustituidas como antagonistas del receptor de la prostaglandina d2
CA2793324A1 (en) 2010-03-16 2011-09-22 Aventis Pharmaceuticals Inc. A substituted pyrimidine as a prostaglandin d2 receptor antagonist
CA2790139C (en) 2010-03-22 2018-03-13 Actelion Pharmaceuticals Ltd 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
US20110237972A1 (en) 2010-03-23 2011-09-29 Robert Garfield Noninvasive measurement of uterine emg propagation and power spectrum frequency to predict true preterm labor and delivery
WO2011128357A2 (en) * 2010-04-13 2011-10-20 Pronota N.V. Biomarkers for hypertensive disorders of pregnancy
EP2569253A4 (en) * 2010-05-14 2013-10-02 Beth Israel Hospital EXTRACORPORAL DEVICES AND METHOD FOR TREATING COMPLICATIONS DURING PREGNANCY
US20110312927A1 (en) 2010-06-18 2011-12-22 Satish Kumar Nachaegari Progesterone Containing Oral Dosage Forms and Related Methods
US20110312928A1 (en) 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
WO2011163554A2 (en) 2010-06-25 2011-12-29 Winthrop-University Hospital Lipocalin-type prostaglandin d2 synthase as a biomarker for lung cancer progression and prognosis
TW201201805A (en) 2010-07-05 2012-01-16 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
AP2013006667A0 (en) 2010-07-12 2013-01-31 Therasyn Sensors Inc A device and methods for in vivo monitoring of an individual
US8765487B2 (en) 2010-09-01 2014-07-01 Clinical Innovations Detection of amniotic fluid in vaginal secretions of pregnant women due to premature rupture of fetal membranes
CN103201628B (zh) 2010-10-01 2015-09-16 霍罗杰克股份有限公司 用于诊断系统中使用的免疫测定测试条
WO2012049316A1 (en) 2010-10-15 2012-04-19 Olink Ab Dynamic range methods
CN103415769B (zh) 2010-12-06 2017-04-12 迈卡蒂斯股份有限公司 用于妊娠性高血压疾病的生物标志物和参数
US20120196285A1 (en) 2011-01-31 2012-08-02 Esoterix Genetic Laboratories, Llc Methods for Enriching Microparticles or Nucleic Acids Using Binding Molecules
GB201101621D0 (en) 2011-01-31 2011-03-16 Olink Ab Method and product
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
JP6034394B2 (ja) 2011-11-09 2016-11-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 切迫妊娠高血圧腎症および／またはＨＥＬＬＰ症候群の指標としてのｓＦｌｔ−１またはエンドグリン／ＰｌＧＦ比の動態
CN104204799A (zh) 2012-02-06 2014-12-10 珀金埃尔默生物信号股份有限公司 双受体时间分辨时间分辨荧光共振能量转移法
HK1206071A1 (en) 2012-05-08 2015-12-31 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for providing a preeclampsia assessment
BR112014029233A8 (pt) 2012-06-27 2019-01-29 Hoffmann La Roche método para diagnosticar se um indivíduo grávido não está em risco, usos de pelo menos um dos biomarcadores sfit-1, endoglina e pigf, dispositivo, kit, método de gestão de um indivíduo, sistema e método para estabelecer um auxílio
EP2890816B1 (en) 2012-08-30 2019-06-05 Ansh Labs LLC Papp-a2 as a marker for monitoring, predicting and diagnosing preeclampsia
WO2014066568A1 (en) 2012-10-24 2014-05-01 Winthrop-University Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
WO2014078622A1 (en) * 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
EP2965088B1 (en) * 2013-03-04 2018-12-05 IQ Products B.V. Prognostic marker to determine the risk for early-onset preeclampsia
CN105917232B (zh) 2013-12-03 2020-10-16 塞尚公司 用于选择性确定胎盘生长因子2的方法
CN105917233B (zh) 2014-01-24 2018-07-03 豪夫迈·罗氏有限公司 产后hellp综合征、产后子痫或产后子痫前期的预测
US10281475B2 (en) 2014-03-27 2019-05-07 Wayne State University Systems and methods to identify and treat subjects at risk for obstetrical complications
MA40325A (fr) 2014-07-30 2016-02-04 Matthew Cooper Procédés et compositions pour diagnostiquer, pronostiquer et confirmer une pré-éclampsie.
EP3259600B1 (en) 2015-02-18 2024-07-24 MirZyme Therapeutics Limited Diagnostic assay and treatment for preeclampsia
WO2016134324A1 (en) 2015-02-20 2016-08-25 Neoteryx, Llc Method and apparatus for acquiring blood for testing
WO2016149759A1 (en) 2015-03-23 2016-09-29 Adelaide Research & Innovation Pty Ltd Methods and systems for determining risk of a pregnancy complication occurring
EP3502705B1 (en) 2015-09-11 2020-09-09 Universidad de los Andes In vitro method for identifying a pregnancy related disease
NL2016967B1 (en) 2016-06-15 2017-12-21 Iq Products B V Markers and their ratio to determine the risk for early-onset preeclampsia.
US20190353667A1 (en) 2017-02-06 2019-11-21 Astute Medical, Inc. Methods and Compositions for Diagnosis and Prognosis of Renal Injury and Renal Failure
US20190079097A1 (en) 2017-09-13 2019-03-14 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
US20200264188A1 (en) 2017-09-13 2020-08-20 Progenity, Inc. Preeclampsia biomarkers and related systems and methods

Also Published As

Publication number Publication date
KR20200109293A (ko) 2020-09-22
WO2019055661A1 (en) 2019-03-21
MX2020002788A (es) 2020-09-14
SG11202002065VA (en) 2020-04-29
WO2019055661A8 (en) 2020-03-26
US20200264188A1 (en) 2020-08-20
US20220268781A1 (en) 2022-08-25
JP2020533595A (ja) 2020-11-19
US11333672B2 (en) 2022-05-17
EP3682250A1 (en) 2020-07-22
AU2018331400A1 (en) 2020-04-02
EP3682250A4 (en) 2021-03-03
US20210293824A1 (en) 2021-09-23
CN111094988A (zh) 2020-05-01

Similar Documents

Publication Publication Date Title
US11333672B2 (en) Preeclampsia biomarkers and related systems and methods
Easter et al. Urinary tract infection during pregnancy, angiogenic factor profiles, and risk of preeclampsia
CN103969455B (zh) 确定产前并发症风险的方法
US20250244317A1 (en) Assessment of preeclampsia using assays for free and dissociated placental growth factor
Wright et al. Serum PlGF compared with PAPP‐A in first trimester screening for preterm pre‐eclampsia: adjusting for the effect of aspirin treatment
Cheng et al. Prognostic value of cardiovascular disease risk factors measured in the first-trimester on the severity of preeclampsia
CN106796241B (zh) 确定先兆子痫风险的方法
US20190079097A1 (en) Preeclampsia biomarkers and related systems and methods
WO2021113710A1 (en) Assessment of preeclampsia using assays for free and dissociated placental growth factor
Shree et al. Association of fetal fraction with hypertensive disorders of pregnancy incidence and disease severity
Singh et al. The prognostic significance of pro-BNP and heart failure in acute pulmonary embolism: A systematic review
Oluwole et al. Analysis of serum placental growth factor levels in preeclamptic and normotensive pregnant women in Lagos, Nigeria: a worthwhile screening tool?
JP2017516119A (ja) 初期胎盤インスリン様ペプチド（プロ（ｐｒｏ）−ＥＰＩＬ）
Elkahlout et al. Application of proteomics in maternal and neonatal health: advancements and future directions
JP7851566B2 (ja) 早発性子癇前症の予後についてのバイオマーカー
Zamudio et al. From pruritus to cholestasis: Building a statistical model and online application to predict a diagnosis prior to bile acid determination
Gilboa et al. A prediction model for hemolysis, elevated liver enzymes and low platelets syndrome in pre‐eclampsia with severe features
JP2016520843A (ja) 心不全後の再入院のバイオマーカー
Hasan Ali Alanbaki et al. Assessment of kisspeptin and trappin level in Iraqi women with early pregnancy loss: a cross sectional study
Ruhle et al. Machine Learning Models for Preterm Birth Prediction Using Vaginal Microbiome Profiles in a Mexican Cohort
Ju et al. Postpartum cardiac complications after hypertensive disorders of pregnancy: predictive roles of retinal arteriolar-to-venular ratio and NT-proBNP
JP2026501110A (ja) 早発性子癇前症の予後についての多重ｓｆｌｔ－１測定
JP2019519795A (ja) 心血管疾患の同定及びリスク評価のための妊娠中の心臓トロポニンｉ検出
HK40129389A (zh) 用於早发型先兆子痫预後的多个sflt-1测量值
Patel et al. High-Sensitivity Troponin I and Coronary Computed Tomography in Symptomatic Outpatients With Suspected CAD

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20240313